Focus: ARQ Genetics is a biotechnology company specializing in real-time gene expression data platforms, with a focus on ophthalmology, gastroenterology, and neurology. The company is actively hiring across 32 open roles, indicating early-to-growth-stage expansion.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
Stable — net +3 jobs in 30d
32 added, 29 removed. Backfill posture.
ARQ Genetics is a speculative early-stage platform play best suited for engineers and scientists with high risk tolerance seeking equity upside and foundational impact in gene expression technology.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for ARQ Genetics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from ARQ Genetics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo